Cargando…

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies

BACKGROUND: Treatment of everolimus-resistant disease remains largely undefined in metastatic renal cell carcinoma (mRCC). We report on 40 patients (pts) who receive systemic treatment after failure of everolimus. PATIENTS AND METHODS: Forty pts received sunitinib (n=19), sorafenib (n=8), dovitinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grünwald, V, Seidel, C, Fenner, M, Ganser, A, Busch, J, Weikert, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3242587/ https://www.ncbi.nlm.nih.gov/pubmed/22033275 http://dx.doi.org/10.1038/bjc.2011.389

Ejemplares similares

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
por: Seidel, C, et al.
Publicado: (2013)

Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study
por: Bergmann, Lothar, et al.
Publicado: (2015)

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
por: Busch, Jonas, et al.
Publicado: (2011)

Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study
por: Nagyiványi, Krisztián, et al.
Publicado: (2019)

CT patterns of organizing pneumonia in patients treated with VEGF/mTOR inhibitors for metastatic renal cell cancer: an observational study
por: Dettmer, Sabine, et al.
Publicado: (2017)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
por: Bracarda, S, et al.
Publicado: (2012)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus
por: Tan, Xiaojie, et al.
Publicado: (2015)

Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma
por: Stenehjem, David D., et al.
Publicado: (2019)

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma
por: Bendtsen, Mathias Alrø Fichtner, et al.
Publicado: (2017)

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy
por: Buti, Sebastiano, et al.
Publicado: (2016)

Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib
por: Billemont, B, et al.
Publicado: (2008)

Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
por: Molina, Ana M., et al.
Publicado: (2010)

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib
por: Serova, Maria, et al.
Publicado: (2016)

The Role of Everolimus in Renal Cell Carcinoma
por: Meskawi, Malek, et al.
Publicado: (2015)

Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)
por: Seidel, Christoph, et al.
Publicado: (2012)

Chronic total occlusion successfully treated with a bioresorbable everolimus-eluting vascular scaffold
por: Rama-Merchan, Juan Carlos, et al.
Publicado: (2014)

Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma
por: Ismayilov, Rashad, et al.
Publicado: (2022)

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma
por: ERIKSSON, Hanna, et al.
Publicado: (2020)

FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer
por: Chen, James L, et al.
Publicado: (2013)

Immunological effects of everolimus in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2017)

Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
por: Sharma, Revati, et al.
Publicado: (2021)

Role of everolimus in the treatment of renal cell carcinoma
por: George, Saby, et al.
Publicado: (2009)

The crucial role of miR-126 on suppressing progression of esophageal cancer by targeting VEGF-A
por: Kong, Ranran, et al.
Publicado: (2016)

Systemic therapy in metastatic renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2016)

Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options?
por: Eggers, Hendrik, et al.
Publicado: (2022)

Cutaneous Adnexal Adenocarcinoma: Genomic Analysis and Successful HER2-targeted Therapy of Metastatic Disease
por: HIRANO-LOTMAN, Yui, et al.
Publicado: (2023)

Detection of let-7 miRNAs in urine supernatant as potential diagnostic approach in non-metastatic clear-cell renal cell carcinoma
por: Fedorko, Michal, et al.
Publicado: (2017)

Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma
por: Chow, Ryan D, et al.
Publicado: (2023)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
por: Huijts, Charlotte M., et al.
Publicado: (2018)

Everolimus-induced activation of latent Mycobacterium tuberculosis infection in a patient with metastatic renal cell carcinoma
por: Jeon, So-Yeon, et al.
Publicado: (2017)

(18)F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma
por: Derlin, Thorsten, et al.
Publicado: (2020)

Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials
por: Bono, Petri, et al.
Publicado: (2016)

Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study)
por: Zeuschner, Philip, et al.
Publicado: (2021)

Targeted therapy for metastatic renal cell carcinoma
por: Patel, P H, et al.
Publicado: (2006)

Targeted Therapy for Metastatic Renal Carcinoma: an Update
por: da Silva, Rodrigo Donalisio, et al.
Publicado: (2014)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer
por: Lieu, Christopher H., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_dqg503a9b4hfqnpf5to0t8gfbk